NCT00771030 is a Phase 1, PHASE2 clinical trial of Brodalumab in Rheumatoid Arthritis, sponsored by Amgen.

Who is sponsoring NCT00771030?

NCT00771030 is sponsored by Amgen.

What drugs are being tested in NCT00771030?

Interventions in NCT00771030: Brodalumab, Placebo.

What condition does NCT00771030 study?

NCT00771030 studies Rheumatoid Arthritis.

Is NCT00771030 still recruiting?

NCT00771030 is currently completed. Last updated 26 November 2021.

Are results published for NCT00771030?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-11-26 · How we verify

NCT00771030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis

Completed Phase 1, PHASE2 Results posted Last updated 26 November 2021

What this trial tests

Phase 1, PHASE2 trial testing Brodalumab in Rheumatoid Arthritis in 40 participants. Completed in 25 May 2010.

Timeline

27 October 2008

Primary endpoint
25 May 2010

25 May 2010

Quick facts

Lead sponsor	Amgen
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	27 October 2008
Primary completion	25 May 2010
Estimated completion	25 May 2010

Drugs / interventions tested

Brodalumab (BRODALUMAB) — full drug profile →
Placebo

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 70, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment-emergent Adverse Events Primary · From first dose of study drug up to end of study (week 19).

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment, including any such occurrence (eg, sign, symptom, or diagnosis) or worsening of a pre-existing medical condition. A serious adverse event was defined as an adverse event that was fatal; was life threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or other significant

Any treatment-emergent adverse event (TEAE)

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	3
Placebo IV (Cohorts 5-6)	4
Brodalumab 50 mg SC (Cohort 1)	5
Brodalumab 140 mg SC (Cohort 2)	5
Brodalumab 210 mg SC (Cohort 3)	4
Brodalumab 420 mg IV (Cohort 5)	5
Brodalumab 700 mg IV (Cohort 6)	4

Serious TEAEs

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	1
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	1
Brodalumab 700 mg IV (Cohort 6)	0

Treatment-related TEAEs

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	1
Placebo IV (Cohorts 5-6)	2
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	3
Brodalumab 210 mg SC (Cohort 3)	2
Brodalumab 420 mg IV (Cohort 5)	2
Brodalumab 700 mg IV (Cohort 6)	0

Treatment-related serious TEAEs

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Discontinuation of study drug due to TEAE

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	1

Deaths on study

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Number of Participants With Clinically Significant Changes in Safety Laboratory Tests Primary · Blood samples were taken on days 2, 8, 15, 29, 43, 57, 71, 85, 106, and 127.

The investigator reviewed laboratory test results and determined whether an abnormal value in an individual study participant represented a change from prestudy values and determined if changes were clinically significant. The number of participants with clinically significant changes in lab values at any time during the study is reported.

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Number of Participants With Clinically Significant Changes in Physical Examination Findings, Vital Signs, or Electrocardiogram Findings Primary · From first dose of study drug up to 4 weeks after last dose; 14 weeks for Cohorts 1, 2, and 3 and 8 weeks for Cohorts 5 and 6.

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Number of Participants With Anti-brodalumab Antibodies Primary · Days 1 (pre-dose), 29 (pre-dose), 85, and 127

Samples were tested in a validated immunoassay for the presence of anti-brodalumab binding antibodies. Samples found to be positive for binding antibodies were further tested using a validated cell-based bioassay to determine if the antibodies were able to neutralize the activity of brodalumab.

Binding antibodies

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	1
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	1
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Neutralizing antibodies

Group	Value	95% CI
Placebo SC (Cohorts 1-3)	0
Placebo IV (Cohorts 5-6)	0
Brodalumab 50 mg SC (Cohort 1)	0
Brodalumab 140 mg SC (Cohort 2)	0
Brodalumab 210 mg SC (Cohort 3)	0
Brodalumab 420 mg IV (Cohort 5)	0
Brodalumab 700 mg IV (Cohort 6)	0

Time to Maximum Concentration of Brodalumab After Single and Multiple Subcutaneous Doses Secondary · After first dose on days 1 (pre-dose and 4 hours post-dose), 2, 3, 5, 8, 11, and 15 (pre-dose), and after last dose on days 71 (pre-dose and 4 hours post-dose), 72, 73, 75, 78, 81, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	1.46	0.18 – 2.00
Brodalumab 140 mg SC (Cohort 2)	3.96	2.00 – 4.00
Brodalumab 210 mg SC (Cohort 3)	2.99	0.97 – 4.00

Day 71 (last dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	2.00	1.13 – 2.09
Brodalumab 140 mg SC (Cohort 2)	3.95	1.93 – 4.07
Brodalumab 210 mg SC (Cohort 3)	4.00	1.02 – 4.02

Maximum Concentration of Brodalumab After Single and Multiple Subcutaneous Doses Secondary · After first dose on days 1 (pre-dose and 4 hours post-dose), 2, 3, 5, 8, 11, and 15 (pre-dose), and after last dose on days 71 (pre-dose and 4 hours post-dose), 72, 73, 75, 78, 81, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	0.742	± 0.522
Brodalumab 140 mg SC (Cohort 2)	5.67	± 2.98
Brodalumab 210 mg SC (Cohort 3)	16.6	± 8.97

Day 71 (last dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	1.35	± 1.07
Brodalumab 140 mg SC (Cohort 2)	5.93	± 5.15
Brodalumab 210 mg SC (Cohort 3)	18.4	± 7.21

Area Under the Concentration-time Curve From Time Zero to the Time of the Final Quantifiable Sample (AUC0-t) for Brodalumab After Single and Multiple Subcutaneous Doses Secondary · After first dose on days 1 (pre-dose and 4 hours post-dose), 2, 3, 5, 8, 11, and 15 (pre-dose), and after last dose on days 71 (pre-dose and 4 hours post-dose), 72, 73, 75, 78, 81, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	1.77	± 1.61
Brodalumab 140 mg SC (Cohort 2)	37.6	± 27.8
Brodalumab 210 mg SC (Cohort 3)	142	± 67.3

Day 71 (last dose)

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	4.13	± 3.20
Brodalumab 140 mg SC (Cohort 2)	50.8	± 51.5
Brodalumab 210 mg SC (Cohort 3)	191	± 82.7

Accumulation Ratio for Brodalumab After Subcutaneous Dosing Secondary · After first dose on days 1 (pre-dose and 4 hours post-dose), 2, 3, 5, 8, 11, and 15 (pre-dose), and after last dose on days 71 (pre-dose and 4 hours post-dose), 72, 73, 75, 78, 81, 85, 106 and 127.

Accumulation was measured by AUC0-t, last dose / AUC0-t, first dose).

Group	Value	95% CI
Brodalumab 50 mg SC (Cohort 1)	24.4	± 51.4
Brodalumab 140 mg SC (Cohort 2)	1.3	± 0.8
Brodalumab 210 mg SC (Cohort 3)	1.5	± 0.6

Time to Maximum Concentration of Brodalumab After Single and Multiple Intravenous Doses Secondary · After first dose on days 1 (pre-dose and 0.5 and 4 hours post-dose), 2, 3, 5, 8, 11, and 15, and after last dose on days 29 (pre-dose and 0.5 and 4 hours post-dose), 30, 31, 33, 36, 39, 43, 57, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	4.07	3.40 – 22.27
Brodalumab 700 mg IV (Cohort 6)	0.92	0.82 – 1.53

Day 29 (last dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	0.98	0.77 – 4.02
Brodalumab 700 mg IV (Cohort 6)	0.83	0.57 – 4.55

Maximum Concentration of Brodalumab After Single and Multiple Intravenous Doses Secondary · After first dose on days 1 (pre-dose and 0.5 and 4 hours post-dose), 2, 3, 5, 8, 11, and 15, and after last dose on days 29 (pre-dose and 0.5 and 4 hours post-dose), 30, 31, 33, 36, 39, 43, 57, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	111	± 19.2
Brodalumab 700 mg IV (Cohort 6)	240	± 44.8

Day 29 (last dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	127	± 12.1
Brodalumab 700 mg IV (Cohort 6)	655	± 949

Area Under the Concentration-time Curve From Time Zero to the Time of the Final Quantifiable Sample (AUC0-t) for Brodalumab After Single and Multiple Intravenous Doses Secondary · After first dose on days 1 (pre-dose and 0.5 and 4 hours post-dose), 2, 3, 5, 8, 11, and 15, and after last dose on days 29 (pre-dose and 0.5 and 4 hours post-dose), 30, 31, 33, 36, 39, 43, 57, 85, 106 and 127.

Day 1 (first dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	831	± 197
Brodalumab 700 mg IV (Cohort 6)	1840	± 602

Day 29 (last dose)

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	951	± 307
Brodalumab 700 mg IV (Cohort 6)	2230	± 998

Accumulation Ratio for Brodalumab After Intravenous Dosing Secondary · After first dose on days 1 (pre-dose and 0.5 and 4 hours post-dose), 2, 3, 5, 8, 11, and 15, and after last dose on days 29 (pre-dose and 0.5 and 4 hours post-dose), 30, 31, 33, 36, 39, 43, 57, 85, 106 and 127.

Accumulation was measured by AUC0-t, last dose / AUC0-t, first dose).

Group	Value	95% CI
Brodalumab 420 mg IV (Cohort 5)	1.1	± 0.2
Brodalumab 700 mg IV (Cohort 6)	1.2	± 0.1

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study drug up to end of study (week 19).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo SC (Cohorts 1-3)

Serious: 1/6 (17%)

Deaths: —

Placebo IV (Cohorts 5-6)

Serious: 0/4 (0%)

Deaths: —

Brodalumab 50 mg SC (Cohort 1)

Serious: 0/6 (0%)

Deaths: —

Brodalumab 140 mg SC (Cohort 2)

Serious: 0/6 (0%)

Deaths: —

Brodalumab 210 mg SC (Cohort 3)

Serious: 0/6 (0%)

Deaths: —

Brodalumab 420 mg IV (Cohort 5)

Serious: 1/6 (17%)

Deaths: —

Brodalumab 700 mg IV (Cohort 6)

Serious: 0/6 (0%)

Deaths: —

Serious adverse events (3 terms)

Reaction	System	Placebo SC (Cohorts 1-3)	Placebo IV (Cohorts 5-6)	Brodalumab 50 mg SC (Cohor…	Brodalumab 140 mg SC (Coho…	Brodalumab 210 mg SC (Coho…	Brodalumab 420 mg IV (Coho…	Brodalumab 700 mg IV (Coho…
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—
Complicated migraine	Nervous system disorders	—	—	—	—	—	—	—

Other adverse events (75 terms — click to expand)

Reaction	System	Placebo SC (Cohorts 1-3)	Placebo IV (Cohorts 5-6)	Brodalumab 50 mg SC (Cohor…	Brodalumab 140 mg SC (Coho…	Brodalumab 210 mg SC (Coho…	Brodalumab 420 mg IV (Coho…	Brodalumab 700 mg IV (Coho…
Leukocytosis	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—	—	—
Ear pain	Ear and labyrinth disorders	—	—	—	—	—	—	—
Conjunctivitis	Eye disorders	—	—	—	—	—	—	—
Dry eye	Eye disorders	—	—	—	—	—	—	—
Lacrimation increased	Eye disorders	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—
Food poisoning	Gastrointestinal disorders	—	—	—	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Odynophagia	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Administration site pain	General disorders	—	—	—	—	—	—	—
Chest discomfort	General disorders	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—
Injection site erythema	General disorders	—	—	—	—	—	—	—
Injection site haematoma	General disorders	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Amoebiasis	Infections and infestations	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—
Fungal skin infection	Infections and infestations	—	—	—	—	—	—	—
Furuncle	Infections and infestations	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—
Laryngitis	Infections and infestations	—	—	—	—	—	—	—

Most-reported serious reactions: Gastrooesophageal reflux disease, Non-cardiac chest pain, Complicated migraine.

Data from ClinicalTrials.gov NCT00771030 adverse events section.

Sponsor's own description

This Phase 1b/2a study will evaluate safety, tolerability pharmacokinetics (PK) and pharmacodynamics (PD) of brodalumab when administered in multiple subcutaneous (SC) and intravenous (IV) doses in patients with active rheumatoid arthritis (RA) in combination with a stable dose of disease modulating anti-rheumatic drugs (DMARDs). Part A is dose escalation (to assess safety \& tolerability), and Part B is dose expansion (to assess clinical efficacy) at the highest tolerated dose level of brodalumab from Part A.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, et al · · 2013 · cited 82× · PMID 24286136 · DOI 10.1186/ar4347
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.
Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, et al · · 2020 · cited 81× · PMID 33244315 · DOI 10.3389/fimmu.2020.565470
Interleukin-17 as a potential therapeutic target for chronic pain.
Jiang X, Zhou R, Zhang Y, Zhu T, et al · · 2022 · cited 33× · PMID 36248896 · DOI 10.3389/fimmu.2022.999407
Transcriptional Interactomic Inhibition of RORα Suppresses Th17-Related Inflammation.
Ho CC, Kim G, Mun CH, Kim JW, et al · · 2021 · PMID 34992408 · DOI 10.2147/jir.s344031

Verify or expand the search:

Other trials of Brodalumab

Trials testing the same drug.

NCT04305327 — Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis · Phase 3 · terminated
NCT04306315 — Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and · Phase 4 · completed
NCT05132231 — Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Wor · active not recruiting
NCT04979520 — Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa · EARLY_PHASE1 · completed
NCT04533737 — Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Respons · Phase 4 · terminated

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00771030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 26 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00771030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT00771030

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (3 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Brodalumab

Other recruiting trials for Rheumatoid Arthritis

Other Amgen trials

Verify against primary sources